Manifold Bio

• 14/07/2022
• Series A
• $40,000,000

A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.

Our mission is to make the best life-saving drugs available to patients as quickly as possible.

We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

---

---